216 related articles for article (PubMed ID: 26228687)
21. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
Loulergue P; Mir O; Sogni P
AIDS; 2012 Mar; 26(5):655-6. PubMed ID: 22398573
[No Abstract] [Full Text] [Related]
22. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
[No Abstract] [Full Text] [Related]
23. Adding telaprevir improves cure rate in patient with HCV infection.
AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
[No Abstract] [Full Text] [Related]
24. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
Medrano J; Barreiro P; Resino S; Tuma P; Rodríguez V; Vispo E; Labarga P; Madejón A; García-Samaniego J; Jiménez-Nácher I; Martín-Carbonero L; Soriano V
Clin Infect Dis; 2009 Nov; 49(9):1397-401. PubMed ID: 19814621
[TBL] [Abstract][Full Text] [Related]
25. I favor therapy for hepatitis C virus recurrence after transplantation.
Samuel D
Liver Transpl; 2002 Oct; 8(10 Suppl 1):S55-8. PubMed ID: 12362300
[No Abstract] [Full Text] [Related]
26. HCV/HIV co-infection therapy.
Pietrandoni G
Posit Aware; 2002; 13(2):32, 38. PubMed ID: 12004829
[No Abstract] [Full Text] [Related]
27. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
[TBL] [Abstract][Full Text] [Related]
28. The epidemiology and control of hepatitis C infection.
Gungabissoon U
Nurs Times; 2003 Aug 5-11; 99(31):24-5. PubMed ID: 13677115
[TBL] [Abstract][Full Text] [Related]
29. PSG consensus statement on management of hepatitis C virus infection--2003.
Hamid S; Umar M; Alam A; Siddiqui A; Qureshi H; Butt J;
J Pak Med Assoc; 2004 Mar; 54(3):146-50. PubMed ID: 15129876
[No Abstract] [Full Text] [Related]
30. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
[No Abstract] [Full Text] [Related]
31. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C
Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540
[TBL] [Abstract][Full Text] [Related]
32. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
Smith JA; Kalimullah FA; Erickson CP; Peng LS
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
[TBL] [Abstract][Full Text] [Related]
33. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
34. Hepatitis C virus infection.
Lauer GM; Walker BD
N Engl J Med; 2001 Jul; 345(1):41-52. PubMed ID: 11439948
[No Abstract] [Full Text] [Related]
35. Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Serfaty L
Liver Int; 2014 Feb; 34 Suppl 1():11-2. PubMed ID: 24373072
[TBL] [Abstract][Full Text] [Related]
36. Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches.
Yeung E; Chung RT
J Hepatol; 2005 Nov; 43(5):748-50. PubMed ID: 16171895
[No Abstract] [Full Text] [Related]
37. [Hepatitis C].
Moradpour D; Blum HE
Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
[TBL] [Abstract][Full Text] [Related]
38. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
[No Abstract] [Full Text] [Related]
39. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
40. Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
Shiffman ML; Rustgi VK
Gastroenterology; 2006 Oct; 131(4):1339-41. PubMed ID: 17030201
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
